Chlorthalidone promotes mineral retention in patients with idopathic hypercalciuria

F. L. Coe; J. H. Parks; D. A. Bushinsky; C. B. Langman; M. J. Favus

doi:10.1038/ki.1988.122

Chlorthalidone promotes mineral retention in patients with idopathic hypercalciuria

F. L. Coe, J. H. Parks, D. A. Bushinsky, C. B. Langman, M. J. Favus

Pediatrics

Research output: Contribution to journal › Article › peer-review

73 Scopus citations

Abstract

In seven patients with severe idiopathic hypercalciuria and recurrent calcium oxalate nephrolithiasis, we have determined the effects on mineral balance of chronic treatment with chlorthalidone or trichlormethiazide, drugs that are widely used to lower urine calcium losses and reduce stone recurrence. Each person excreted above 350 mg of calcium daily while untreated, and was studied twice, before and after three to six months of treatment. Compared to pretreatment, the drugs reduced intestinal calcium absorption; but they reduced urine calcium loss even more, so calcium retention increased. Phosphate retention also increased. Serum levels of calcitriol, parathyroid hormone, calcium, phosphate, and magnesium were unchanged. At least in patients of this type, chlorthalidone and trichlormethiazide seem ideal treatments, that lower urine calcium yet increase calcium and phosphate retention. Whether patients with less severe hypercalciuria respond this way is unknown.

Original language	English (US)
Pages (from-to)	1140-1146
Number of pages	7
Journal	Kidney international
Volume	33
Issue number	6
DOIs	https://doi.org/10.1038/ki.1988.122
State	Published - 1988

ASJC Scopus subject areas

Nephrology

Access to Document

10.1038/ki.1988.122

Cite this

@article{dfb40bc0ec364711a3b59cc588202dfb,

title = "Chlorthalidone promotes mineral retention in patients with idopathic hypercalciuria",

abstract = "In seven patients with severe idiopathic hypercalciuria and recurrent calcium oxalate nephrolithiasis, we have determined the effects on mineral balance of chronic treatment with chlorthalidone or trichlormethiazide, drugs that are widely used to lower urine calcium losses and reduce stone recurrence. Each person excreted above 350 mg of calcium daily while untreated, and was studied twice, before and after three to six months of treatment. Compared to pretreatment, the drugs reduced intestinal calcium absorption; but they reduced urine calcium loss even more, so calcium retention increased. Phosphate retention also increased. Serum levels of calcitriol, parathyroid hormone, calcium, phosphate, and magnesium were unchanged. At least in patients of this type, chlorthalidone and trichlormethiazide seem ideal treatments, that lower urine calcium yet increase calcium and phosphate retention. Whether patients with less severe hypercalciuria respond this way is unknown.",

author = "Coe, {F. L.} and Parks, {J. H.} and Bushinsky, {D. A.} and Langman, {C. B.} and Favus, {M. J.}",

year = "1988",

doi = "10.1038/ki.1988.122",

language = "English (US)",

volume = "33",

pages = "1140--1146",

journal = "Kidney International",

issn = "0085-2538",

publisher = "Nature Publishing Group",

number = "6",

}

TY - JOUR

T1 - Chlorthalidone promotes mineral retention in patients with idopathic hypercalciuria

AU - Coe, F. L.

AU - Parks, J. H.

AU - Bushinsky, D. A.

AU - Langman, C. B.

AU - Favus, M. J.

PY - 1988

Y1 - 1988

N2 - In seven patients with severe idiopathic hypercalciuria and recurrent calcium oxalate nephrolithiasis, we have determined the effects on mineral balance of chronic treatment with chlorthalidone or trichlormethiazide, drugs that are widely used to lower urine calcium losses and reduce stone recurrence. Each person excreted above 350 mg of calcium daily while untreated, and was studied twice, before and after three to six months of treatment. Compared to pretreatment, the drugs reduced intestinal calcium absorption; but they reduced urine calcium loss even more, so calcium retention increased. Phosphate retention also increased. Serum levels of calcitriol, parathyroid hormone, calcium, phosphate, and magnesium were unchanged. At least in patients of this type, chlorthalidone and trichlormethiazide seem ideal treatments, that lower urine calcium yet increase calcium and phosphate retention. Whether patients with less severe hypercalciuria respond this way is unknown.

AB - In seven patients with severe idiopathic hypercalciuria and recurrent calcium oxalate nephrolithiasis, we have determined the effects on mineral balance of chronic treatment with chlorthalidone or trichlormethiazide, drugs that are widely used to lower urine calcium losses and reduce stone recurrence. Each person excreted above 350 mg of calcium daily while untreated, and was studied twice, before and after three to six months of treatment. Compared to pretreatment, the drugs reduced intestinal calcium absorption; but they reduced urine calcium loss even more, so calcium retention increased. Phosphate retention also increased. Serum levels of calcitriol, parathyroid hormone, calcium, phosphate, and magnesium were unchanged. At least in patients of this type, chlorthalidone and trichlormethiazide seem ideal treatments, that lower urine calcium yet increase calcium and phosphate retention. Whether patients with less severe hypercalciuria respond this way is unknown.

UR - http://www.scopus.com/inward/record.url?scp=0023952569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023952569&partnerID=8YFLogxK

U2 - 10.1038/ki.1988.122

DO - 10.1038/ki.1988.122

M3 - Article

C2 - 3404813

AN - SCOPUS:0023952569

SN - 0085-2538

VL - 33

SP - 1140

EP - 1146

JO - Kidney International

JF - Kidney International

IS - 6

ER -

Chlorthalidone promotes mineral retention in patients with idopathic hypercalciuria

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this